David William Will,George Reid,Iryna Charapitsa,Joe Lewis
申请号：
US16621608
公开号：
US20200216435A1
申请日:
2018.06.14
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present invention relates to compounds of the formula I as described below or a tautomer or a pharmaceutically acceptable salt thereof； to a pharmaceutical composition containing such compounds； and to said compounds of the formula I or a tautomer or a pharmaceutically acceptable salt thereof for use as a medicament, especially for use in the treatment or prevention of a disease or disorder selected from the group consisting of an inflammatory disease, a hyperproliferative disease or disorder, a hypoxia-related pathology and a disease characterized by excessive vascularization, wherein X1 is CR1 or N； X2 is CR2 or N； X3 is CR3 or N； X4 is CR4 or N； Y1 is N, NR5a, S, O or CR5b； Y2 is N, NR5c, S, O or CR5d； Z is N or C； with the proviso that at most two of X1, X2, X3 and X4 are N； with the proviso that Y1 is not O if Y2 is CR5d and simultaneously Z is C； with the proviso that Y1 and Y2 are not both simultaneously O or S； with the proviso that at least one of Y1, Y2 and Z is a heteroatom or heteroatom-containing group； L1 is a bond, optionally substituted C1-C6-alkylene or C3-C8-cycloalkylene； L2 is a bond, optionally substituted C1-C6-alkylene, C3-C8-cycloalkylene etc.； A is 3-, 4-, 5-, 6-, 7- or 8-membered optionally substituted, saturated, partially unsaturated or maximally unsaturated carbocyclic or heterocyclic ring； or L2-A forms a group C1-C6-alkylene-OR13, C1-C6-alkylene-SR14 or C1-C6-alkylene-NR15SR16； and R1, R2, R3, R4, R5a, R5b, NR5c, R5d, R6, R13, R14, R15 and R16 are as defined in the claims and the description.
